The DeepSleep CSS-7 is a cryogenic suspension system that preserves living humans in a state of metabolic arrest for extended periods. The system cools the subject to -196 degrees Celsius over a carefully controlled 4-hour process, replacing blood and cellular fluid with a vitrification solution that prevents ice crystal formation — the primary cause of tissue damage in earlier cryopreservation attempts. The subject is then maintained in a sealed pod filled with liquid nitrogen, monitored by redundant sensor systems that track cellular integrity at the molecular level.

Revival takes approximately 8 hours and involves gradual warming, vitrification solution removal, blood restoration, and neural stimulation to restart brain activity. The process has a success rate of 99.7% for suspension periods under 5 years, declining to 97.2% for periods between 5 and 20 years, and to 91.8% for periods exceeding 20 years. The 8.2% failure rate for long-term suspension — representing irreversible neural damage during revival — is the system's most significant limitation and the subject of intensive ongoing research by Lazarus's cryobiology division.

Lazarus markets DeepSleep for three primary applications: medical suspension of patients with currently untreatable conditions who wait for future cures, long-duration space transit where the alternative is years of conscious travel, and — most controversially — voluntary temporal displacement by individuals who wish to skip ahead in time. A DeepSleep suspension costs 50,000 Φ for the initial process plus 2,000 Φ per year of maintenance, making it accessible to upper-tier individuals but not to the general population. Lazarus maintains approximately 12,000 active suspension pods worldwide, with occupants ranging from terminal patients to wealthy eccentrics who decided they would prefer the 23rd century.